A number of research firms have changed their ratings and price targets for Longboard Pharmaceuticals (NASDAQ: LBPH):
- 7/11/2024 – Longboard Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $36.00 to $60.00. They now have an “outperform” rating on the stock.
- 7/2/2024 – Longboard Pharmaceuticals had its price target raised by analysts at Evercore ISI from $57.00 to $80.00. They now have an “outperform” rating on the stock.
- 7/2/2024 – Longboard Pharmaceuticals had its price target raised by analysts at Citigroup Inc. from $40.00 to $45.00. They now have a “buy” rating on the stock.
- 7/1/2024 – Longboard Pharmaceuticals had its price target raised by analysts at Cantor Fitzgerald from $60.00 to $90.00. They now have an “overweight” rating on the stock.
- 6/20/2024 – Longboard Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.
- 6/20/2024 – Longboard Pharmaceuticals had its price target raised by analysts at Evercore ISI from $44.00 to $57.00. They now have an “outperform” rating on the stock.
- 6/11/2024 – Longboard Pharmaceuticals had its price target raised by analysts at B. Riley from $30.00 to $36.00. They now have a “buy” rating on the stock.
- 6/11/2024 – Longboard Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Longboard Pharmaceuticals Stock Up 2.3 %
Shares of LBPH traded up $0.83 during mid-day trading on Monday, reaching $36.78. The company’s stock had a trading volume of 547,765 shares, compared to its average volume of 946,772. Longboard Pharmaceuticals, Inc. has a 1 year low of $3.60 and a 1 year high of $40.48. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -16.42 and a beta of 1.24. The business has a fifty day moving average of $24.26 and a 200 day moving average of $22.21.
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.06. On average, analysts predict that Longboard Pharmaceuticals, Inc. will post -1.82 earnings per share for the current year.
Hedge Funds Weigh In On Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
Recommended Stories
- Five stocks we like better than Longboard Pharmaceuticals
- What Does Downgrade Mean in Investing?
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- The 3 Best Blue-Chip Stocks to Buy Now
- Has This Leading Tech Stock Halted the AI Surge?
- How to Use the MarketBeat Excel Dividend Calculator
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Longboard Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.